临床缓解期类风湿关节炎患者亚临床腱鞘炎患病率与治疗的关系:STARTER研究
本研究为STARTER研究的亚组分析,纳入427例连续类风湿关节炎患者,按基线治疗分为bDMARD单药、csDMARD单药及csDMARD+bDMARD联合治疗三组,在基线、6个月和12个月进行临床及超声评估。256例完成观察期,结果显示联合治疗组GS腱鞘炎和PD腱鞘炎控制优于csDMARD单药组(P=0.025和P=0.047),PD滑膜炎缓解优于csDMARD单药组(P=0.01)和bDMARD单药组(P=0.02)。
要点
- 联合治疗组GS腱鞘炎和PD腱鞘炎控制优于csDMARD单药组,P值分别为0.025和0.047。
- 联合治疗组PD滑膜炎缓解优于csDMARD单药组(P=0.01)和bDMARD单药组(P=0.02)。
- 联合治疗组超声检出的亚临床炎症表现患病率低于单药治疗组。
核心结论
- 联合治疗组超声检出的亚临床炎症表现患病率低于单药治疗组。
研究设计与样本
- 本研究为STARTER研究患者队列的亚组分析,于2013年10月至2014年6月连续纳入427例确诊类风湿关节炎患者。
- 按基线治疗分为bDMARD单药组、csDMARD单药组和csDMARD+bDMARD联合治疗组,在基线、6个月和12个月进行28关节临床检查和超声评估。
- 采用OMERACT评分系统计算灰阶(GS)和能量多普勒(PD)滑膜炎及腱鞘炎评分。
- 256例完成观察期:bDMARD组48例(18.75%),csDMARD组152例(59.38%),csDMARD+bDMARD组56例(21.88%)。
主要发现
- 联合治疗组GS腱鞘炎控制优于csDMARD单药组(P=0.025)。
- 联合治疗组PD腱鞘炎控制优于csDMARD单药组(P=0.047)。
- 联合治疗组PD滑膜炎缓解优于csDMARD单药组(P=0.01)。
- 联合治疗组PD滑膜炎缓解优于bDMARD单药组(P=0.02)。
关键数值与推荐
- 联合治疗组GS腱鞘炎与csDMARD单药组比较P=0.025。
- 联合治疗组PD腱鞘炎与csDMARD单药组比较P=0.047。
- 联合治疗组PD滑膜炎与csDMARD单药组比较P=0.01,与bDMARD单药组比较P=0.02。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study is a sub-analysis from the patient cohort of the STARTER (Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission) study. The aim was to evaluate differences in ultrasound-detected joint and/or tendon involvement between patients receiving therapies based on a combination of conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs) and those who were treated with either csDMARDs or bDMARDs in monotherapy. MATERIAL AND METHODS: Four hundred and twenty-seven consecutive patients with a diagnosis of RA were recruited between October 2013 and June 2014. They were divided into three subgroups based on their therapy at baseline: patients with bDMARD in monotherapy, patients with csDMARD in monotherapy and patients in combination therapy (csDMARD + bDMARD). At baseline, 6 months and 12 months, a clinical examination (28 joint count) and an ultrasound evaluation were performed in each patient. A score of grey-scale (GS) and power Doppler (PD) synovitis and tenosynovitis was calculated based on the OMERACT scoring systems. RESULTS: Two hundred and fifty-six patients completed the observation period: 48 patients from the bDMARD group (18.75%), 152 patients from the csDMARD group (59.38%) and 56 patients from csDMARD + bDMARD group (21.88%). The analysis showed that GS tenosynovitis and PD tenosynovitis are better controlled in combination therapy than they are with csDMARD alone (P = 0.025 and P = 0.047, respectively); for PD synovitis, there was a better response in those who were treated with the combination therapy when compared with the patients receiving csDMARD (P = 0.01) or bDMARD (P = 0.02) alone. CONCLUSIONS: The analysis showed a lower prevalence of subclinical inflammatory manifestations detected with ultrasound imaging in those patients treated with the combination therapy than in those in monotherapy.
引用
- Parisi S, Zanetti A, Carrara G, et al. Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study. Rheumatology (Oxford). 2023. PMID: 36066434. doi:10.1093/rheumatology/keac518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。